...
机译:近视脉络膜新生血管中的ranibizumab两种不同的初始治疗方案:随机对照研究的12个月结果
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
Scientific Supporting Department Bothwin Pte. Ltd. Branch of Clinical Epidemiology and Evidence;
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
State Key Laboratory of Ophthalmology Retina DivisionZhongshan Ophthalmic Center Sun Yat‐sen;
clinical trial; mCNV; myopic choroidal neovascularization; ranibizumab; treatment;
机译:近视脉络膜新生血管中的ranibizumab两种不同的初始治疗方案:随机对照研究的12个月结果
机译:在近视脉络膜新生血管中的雷尼兹米亚布两种不同的初始治疗方案:随机对照研究评论的12个月结果
机译:近视脉络膜新生血管中的雷尼兹米亚布的两种不同初始治疗方案:随机对照研究的12个月结果 - 反应
机译:经瞳孔热疗法治疗年龄相关性黄斑变性的脉络膜新生血管
机译:与对照相比,采用两种短期疗程预防结核病,两个月利福平和吡嗪酰胺治疗或仅四个月利福平治疗,评估毒性和患者依从性的随机对照试验结果六个月异烟肼的治疗方案。
机译:雷尼珠单抗连续近三个月度玻璃体内注射治疗近视脉络膜新生血管的12个月结果
机译:近视脉络膜新生血管中的ranibizumab两种不同的初始治疗方案:随机对照研究的12个月结果